Navigation Links
WellPoint Reports Fourth Quarter and Full Year 2007 Results
Date:1/23/2008

> the entire year ended December 31, 2004.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This document contains certain forward-looking information about WellPoint, Inc. ("WellPoint") that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not generally historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)", "intend", "estimate", "project" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of WellPoint, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: those discussed and identified in public filings with the U.S. Securities and Exchange Commission ("SEC") made by WellPoint; increased government regulation of health benefits, managed care and pharmacy benefit management operations; trends in health care costs and utilization rates; our ability to secure sufficient premium rate increases; our ability to contract with providers consistent with past practice; competitor pricing below market trends of increasing costs; reduced enrollment, as well as a negative change in our health care product mix; risks and uncertainties regarding the Medicare Part D Prescription Drug benefits program, including potential uncollectability of receivables resulting from proces
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. WellPoint Announces Consumer Innovation Opportunity
2. WellPoint Appoints Brian A. Sassi as President and CEO of the Companys Consumer Business Unit
3. WellPoint Executive Mark Boxer Recognized as One of Computerworlds 2008 Premier 100 IT Leaders
4. WellPoint Announces Appointment of John Langenus as President of Anthem National Accounts
5. WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
6. WellPoint Announces Appointment of John Cannon III as Executive Vice President & General Counsel
7. WellPoint Provides Support and Resources to Most Vulnerable California Residents
8. WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors
9. WellPoint Reports Third Quarter 2007 Results
10. WellPoint NextRx Receives National Leadership Award for Innovative Web Tool
11. Wellpoint NextRx Receives TIPPS Certification from the HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Blue Cross Blue Shield of Michigan announced ... Care Network and BCN,s current vice president for products ... the state,s largest health maintenance organization when Carlson retires ... was announced today by Daniel J. Loepp, president and ... The appointment is pending formal approval from the ...
(Date:12/17/2009)... advice most effective when it comes from physician, study ... pediatrician,s advice has the most influence in convincing parents ... sleep in order to prevent sudden infant death syndrome, ... government launched the "Back to Sleep" campaign in 1994, ... sleep time has increased from 25 percent to 70 ...
(Date:12/17/2009)... the Fisher Theatre on Dec. 17 for the Detroit-area,premiere of the ... be the real stars of the show. , , ... ... stage at the Fisher Theatre on Dec. 17 for the Detroit-area ... and cancer survivors will be the real stars of the ...
(Date:12/17/2009)... thought-leaders in inflammatory bowel disease (IBD) research were awarded ... Awards at its 2009 Advances in Inflammatory Bowel Diseases ... Florida on December 4th. , ... ... 2009 -- Three clinical and scientific thought-leaders in inflammatory ...
(Date:12/17/2009)... Reportlinker.com announces that a new ... catalogue: ,, http://www.reportlinker.com/p0169956/Top-Ten-Worlds-Leading-Animal-Health-Companies.html ,, ... animal health industry executives with strategically significant ... the development and implementation of effective marketing ... include: ,, To establish a ...
Breaking Medicine News(10 mins):Health News:Doctor's Orders Influence Baby's Sleep Position 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 3Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 2Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 3Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 4Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 5Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 4
... Tommy John teams up with Long Island, NY based New Vitality to ... to address the lifestyle needs of active men and women of all ... ... (PRWEB) December 11, 2008 -- The name of baseball legend Thomas Edward ...
... provider of Electronic Medical Record and practice billing solutions for the ... the company as Chief Commercial Officer. Flormann brings 25 years ... and business and market development to Glenwood Systems. , ... ...
... DC, December 11, 2008-- An independent review investigating the ... has found that the campaign has been associated with ... the December issue of Prevention Science , a ... (SPR)., The Montana Meth Project (MMP) was created in ...
... Inc. (Nasdaq: VTAL ) , ... has named Ray A. Ghanbari, Ph.D., Executive Vice President of ... to President and Chief Executive Officer Michael H. Carrel. In ... marketing, corporate development and driving strategic business planning. , ...
... Dec. 10 Basic government services are not being provided ... and other communicable diseases are rampant. Staggering inflation and unemployment ... that 300,000 people remain at risk of cholera, which is ... lack of functioning sanitation services. To date, the outbreak has ...
... Some are genetically driven to eat more calories, study ... people may be genetically driven to seek out more ... Dec. 11 issue of the New England Journal ... a particular gene variant tend to eat more energy-dense ...
Other Medicine News:Health News:Tommy John Is Now 'Pitching' For GoFlex Joint Formula 2Health News:Tommy John Is Now 'Pitching' For GoFlex Joint Formula 3Health News:Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer 2Health News:Success of anti-meth ads questioned by study 2Health News:Success of anti-meth ads questioned by study 3Health News:Vital Images Names Healthcare Veteran Ray Ghanbari Executive Vice President of Strategy and Products 2Health News:Vital Images Names Healthcare Veteran Ray Ghanbari Executive Vice President of Strategy and Products 3Health News:Gene May Make Kids Crave Junk Food 2Health News:Gene May Make Kids Crave Junk Food 3
(Date:12/17/2009)... -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... four weeks for the first dose cohort, 200 mg bid, ... with pegylated interferon and ribavirin (SOC) in HCV patients. ... of virus (<15 IU/ml) at week 4, known as ... compared to 20% of patients receiving placebo plus SOC. ...
(Date:12/17/2009)... -- Pharmaceutical Institute today announced that it has ... specializing in life science courseware. These assets, ... Institute,s already extensive library of training resources. ... of specialized training solutions for the pharmaceutical and ... Financial terms of the agreement were not ...
(Date:12/17/2009)... -- BASF today announced that the ... of Aseptrol® S10 - Tab in H1N1 sanitization ... schools, hospitals, government buildings, retail and restaurants, and ... based on Chlorine dioxide (CIO2) release technology. ,, ... spectrum disinfectant as stated in the EPA label ...
Breaking Medicine Technology:ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 2ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 3ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 4ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 5ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 6ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 7Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 2BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 3Studies Quantify Cancer Risks From CT Scans 63248 1Studies Quantify Cancer Risks From CT Scans 63248 2Studies Quantify Cancer Risks From CT Scans 63248 3Studies Quantify Cancer Risks From CT Scans 63248 4UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 63244 1UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 63244 2Scientists isolate new antifreeze molecule in Alaska beetle 11142 1Scientists isolate new antifreeze molecule in Alaska beetle 11142 2
... DIEGO, Dec. 8, 2008 Forest Laboratories, Inc. (NYSE: ... CYPB ) today announced positive top-line results ... study of milnacipran for the management of fibromyalgia. ... previous phase III trials, showed that milnacipran demonstrated a ...
... Dec. 8 Cell Therapeutics, Inc. (CTI),(Nasdaq ... follow-up data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line ... of Hematology (ASH) 50th Annual Meeting by,Morschhauser, ... progression-free,survival (PFS) following Zevalin consolidation therapy for ...
Other Medicine Technology:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 5Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5
... you need quick, accurate, convenient, and cost-effective ... VITROS DT60 II Chemistry System. This easy-to-use ... back-up laboratory testing requirements. And it helps ... better patient outcomes, reduced overall costs, and ...
... provides power and efficiency to ... volume testing facilities. With fast ... results per hour, the Vitros ... the full complement of Vitros ...
... Abbott entered the Therapeutic Drug Monitoring ... the TDx. Still in use today, this ... Polarization Immunoassay) to measure serum drug concentration ... the treatment of different diseases, often exhibit ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: